PRMT5 INHIBITORS
The present invention provides a compound selected from: and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are PRMT5 inhibitors. Also provided are methods of making compounds disclosed herein, pharmaceutical compositions comprising compounds disclosed herein, and methods...
Saved in:
Main Authors | , , , , , |
---|---|
Format | Patent |
Language | English Spanish |
Published |
23.09.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The present invention provides a compound selected from: and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are PRMT5 inhibitors. Also provided are methods of making compounds disclosed herein, pharmaceutical compositions comprising compounds disclosed herein, and methods of using these compounds to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.
La presente invención proporciona un compuesto seleccionado de: (ver Fórmulas) y las sales, ésteres y profármacos farmacéuticamente aceptables de los mismos, que son inhibidores de PRMT5. También se proporcionan métodos para hacer compuestos descritos en la presente, composiciones farmacéuticas que comprenden los compuestos descritos en la presente y métodos para usar estos compuestos para tratar el cáncer, células falciformes y persistencia hereditaria de mutaciones de la hemoglobina fetal (HPFH). |
---|---|
AbstractList | The present invention provides a compound selected from: and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are PRMT5 inhibitors. Also provided are methods of making compounds disclosed herein, pharmaceutical compositions comprising compounds disclosed herein, and methods of using these compounds to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.
La presente invención proporciona un compuesto seleccionado de: (ver Fórmulas) y las sales, ésteres y profármacos farmacéuticamente aceptables de los mismos, que son inhibidores de PRMT5. También se proporcionan métodos para hacer compuestos descritos en la presente, composiciones farmacéuticas que comprenden los compuestos descritos en la presente y métodos para usar estos compuestos para tratar el cáncer, células falciformes y persistencia hereditaria de mutaciones de la hemoglobina fetal (HPFH). |
Author | WITTER David J ALTMAN Michael D MACHACEK Michelle SLOMAN David L KAWAMURA Shuhei GIBEAU Craig R |
Author_xml | – fullname: MACHACEK Michelle – fullname: WITTER David J – fullname: SLOMAN David L – fullname: GIBEAU Craig R – fullname: KAWAMURA Shuhei – fullname: ALTMAN Michael D |
BookMark | eNrjYmDJy89L5WQQCAjyDTFV8PTz8HTyDPEPCuZhYE1LzClO5YXS3AxKbq4hzh66qQX58anFBYnJqXmpJfG-EUYGRkYGBuamxiaOxkQpAgAE3h_E |
ContentType | Patent |
DBID | EVB |
DatabaseName | esp@cenet |
DatabaseTitleList | |
Database_xml | – sequence: 1 dbid: EVB name: esp@cenet url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP sourceTypes: Open Access Repository |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Chemistry Sciences |
DocumentTitleAlternate | INHIBIDORES DE PRMT5. |
ExternalDocumentID | MX2022007534A |
GroupedDBID | EVB |
ID | FETCH-epo_espacenet_MX2022007534A3 |
IEDL.DBID | EVB |
IngestDate | Fri Oct 04 04:57:00 EDT 2024 |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | false |
Language | English Spanish |
LinkModel | DirectLink |
MergedId | FETCHMERGED-epo_espacenet_MX2022007534A3 |
Notes | Application Number: MX2022007534 |
OpenAccessLink | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220923&DB=EPODOC&CC=MX&NR=2022007534A |
ParticipantIDs | epo_espacenet_MX2022007534A |
PublicationCentury | 2000 |
PublicationDate | 20220923 |
PublicationDateYYYYMMDD | 2022-09-23 |
PublicationDate_xml | – month: 09 year: 2022 text: 20220923 day: 23 |
PublicationDecade | 2020 |
PublicationYear | 2022 |
RelatedCompanies | MERCK SHARP & DOHME LLC |
RelatedCompanies_xml | – name: MERCK SHARP & DOHME LLC |
Score | 3.2687016 |
Snippet | The present invention provides a compound selected from: and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are PRMT5 inhibitors.... |
SourceID | epo |
SourceType | Open Access Repository |
SubjectTerms | CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES |
Title | PRMT5 INHIBITORS |
URI | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220923&DB=EPODOC&locale=&CC=MX&NR=2022007534A |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwY2BQAR1KBpr90TVMNTfTNUlONNVNTDJL1jW1SDEySkqyTDJNAq_y9TPzCDXxijCNYGLIhu2FAZ8TWg4-HBGYo5KB-b0EXF4XIAaxXMBrK4v1kzKBQvn2biG2LmrQ3rGRkQGwwaLm4mTrGuDv4u-s5uxs6xuh5hcEkQNWj8YmjswMrMB2tDkoO7iGOYG2pRQg1yluggxsAUDj8kqEGJhSi4UZOJ1hV68JM3D4Qme8gUxo5isWYRAICPINMVXw9PPwdPIM8Q8KFmVQcnMNcfbQBRodD_dIvG8EkjOMxRhYgD38VAkGBQOLZFPzxGQD42RghWpulmyZYphikWKQmGiSZG6ZZGYoySCNxyApvLLSDFwgHmiJg5GxDANLSVFpqiywHi1JkgP7HwAyY3Mb |
link.rule.ids | 230,309,783,888,25576,76876 |
linkProvider | European Patent Office |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1JS8QwFH6Mozie1NFBHZdBpLdit3Q5FHG60Op0oVbprTRpDyLoYCv-fZPY0TnNLeTBIwl8-d7LWwJww5qSseiPKDeGLmqkQmKFdSIis1YUjC2MMM_yjfXgWXsoUDGAt1UtDO8T-s2bI1JEEYr3jt_Xy_9HLJfnVra3-JVOfdz5ue0KvXesKBI1WAR3bntp4iaO4Dh2VAhx9iuj9Khq91uwTW1sg8HBe5mzspTlOqf4B7CTUnXv3SEMmnYMI2f19doYdqM-4k2HPfjaI9hPsyhHszAOwnmYJ9nTMVz7Xu4EIlVd_m2kjIq1ZagTGFIPvzmBmWQSZFREUgklVEMnVi3XZi1VlYYNC-vyKUw3KDrbKL2CUZBHi3IRxo9T2GMSlu6gqOcw7D6_mgvKqR2-5GfxA8JQdg4 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=PRMT5+INHIBITORS&rft.inventor=MACHACEK+Michelle&rft.inventor=WITTER+David+J&rft.inventor=SLOMAN+David+L&rft.inventor=GIBEAU+Craig+R&rft.inventor=KAWAMURA+Shuhei&rft.inventor=ALTMAN+Michael+D&rft.date=2022-09-23&rft.externalDBID=A&rft.externalDocID=MX2022007534A |